Delcath Systems, Inc. filings document an interventional oncology company with Nasdaq-listed common stock and a liver-directed drug-device platform. Form 8-K reports furnish quarterly and annual financial results, preliminary results, Regulation FD presentations, product revenue for HEPZATO KIT and CHEMOSAT, clinical publication updates for CHOPIN, and board-authorized share repurchase activity.
The company’s proxy materials cover annual meeting governance, executive compensation, equity awards, and related shareholder voting disclosures. Delcath filings also identify its common stock, par value, trading symbol DCTH, and Nasdaq Capital Market listing, while formal exhibits provide press releases and corporate presentations used for operating, clinical, and capital-structure disclosures.
DELCATH SYSTEMS, INC. director Aharon Gil received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and were awarded as compensation, not through an open-market purchase or sale.
The grant vests in equal monthly installments of one-twelfth of the total, starting on May 13, 2026, so long as Gil remains a director and subject to the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from grant or two years after service ends.
Delcath Systems, Inc. reported the results of its 2026 annual meeting of stockholders, where investors approved increasing the 2020 Omnibus Equity Incentive Plan by 1,800,000 shares of common stock. The plan provides additional shares for future equity-based awards to employees, directors and other participants.
Stockholders also elected two Class II directors to serve until the 2029 annual meeting, ratified CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2026, and approved a non-binding advisory vote on executive compensation. Of 34,618,159 eligible common and convertible preferred shares, 23,346,271 shares, or about 67.44%, were represented at the meeting, indicating a solid voting turnout.
Delcath Systems, Inc. reported first-quarter 2026 revenue of $24.99 million, up from $19.78 million a year earlier, driven by continued uptake of the HEPZATO KIT in the United States. CHEMOSAT contributed $1.75 million, roughly flat year over year.
Gross profit rose to $21.26 million, but higher research and development spending of $9.82 million and selling, general and administrative expenses of $13.07 million led to a net loss of $1.07 million, compared with net income of $1.07 million in the prior-year quarter.
The company ended March 31, 2026 with $41.3 million in cash and cash equivalents and $48.0 million in short-term investments, and believes this liquidity will fund operations for at least 12 months. Delcath is advancing Phase 2 trials of HEPZATO in liver-dominant metastatic colorectal and breast cancer and continues a share repurchase program, having bought back approximately $9.0 million of stock under a $25.0 million authorization.
Delcath Systems reported first quarter 2026 revenue of $25.0 million, up from $19.8 million a year earlier, driven by $23.3 million from HEPZATO KIT and $1.7 million from CHEMOSAT. Gross margin was 85%.
The company posted a net loss of $1.1 million versus net income of $1.1 million in the prior-year quarter, and non-GAAP adjusted EBITDA declined to $3.4 million from $7.6 million. Delcath ended March 31, 2026 with $89.3 million in cash and investments and no debt, and repurchased 316,023 shares for about $3.0 million.
For full-year 2026, Delcath expects total HEPZATO KIT and CHEMOSAT revenue of at least $100 million, gross margins between 84% and 87%, and positive adjusted EBITDA. The quarter also featured publication of Phase 2 CHOPIN trial results and new clinical guideline recognition for CHEMOSAT.
BlackRock, Inc. reports 1,733,824 shares of DELCATH SYS INC common stock, representing 4.98% of the class as of 03/31/2026. The filing shows sole voting power for 1,703,693 shares and sole dispositive power for 1,733,824 shares. The filing is a Schedule 13G/A amendment reporting ownership by BlackRock Reporting Business Units.
Delcath Systems, Inc. is asking stockholders to vote at a virtual annual meeting on May 13, 2026. Proposals include electing two Class II directors, Elizabeth Czerepak and John R. Sylvester, and approving an amendment to the 2020 Omnibus Equity Incentive Plan.
The equity plan amendment would add 1,800,000 shares of common stock to the plan, for a total reserve of 11,125,000 shares, which the Board describes as less than 5% of common share equivalents and sufficient for about one year of grants. Stockholders will also be asked to ratify CBIZ CPAs P.C. as independent auditor for 2026 and to approve, on an advisory basis, named executive officer compensation.
Delcath Systems, Inc. ownership filing shows Daniel Kaufman reports beneficial ownership of 1,766,432 shares of Common Stock, representing 5.08% of the class as reported on 03/18/2026. The filing is a Schedule 13G disclosure of an equity stake by an individual investor.
DELCATH SYSTEMS, INC. Chief Financial Officer Sandra Pennell reported an open-market purchase of common stock. She bought 5,533 shares of Delcath Systems common stock at a price of $9.04 per share. Following this transaction, she directly owned a total of 77,018 common shares, which includes 10,433 shares acquired under the company’s 2021 Employee Stock Purchase Plan.
Delcath Systems filed an 8-K to share that full results from the investigator-initiated Phase 2 CHOPIN trial in metastatic uveal melanoma have been published in The Lancet Oncology. The study tested percutaneous hepatic perfusion (PHP) with Delcath’s CHEMOSAT Hepatic Delivery System alone or combined with ipilimumab and nivolumab in 76 patients.
The company highlights that combining PHP with dual immunotherapy more than tripled the 1-year progression-free survival rate and nearly doubled the 2-year overall survival compared with PHP alone, while also improving liver disease control and depth of response. Safety trade-offs were notable: grade 3 or higher treatment-related adverse events occurred in 82% of patients in the combination arm versus 41% in the PHP-alone arm, with one treatment-related death reported, though most events were described as manageable and without new safety signals.
Delcath frames these data as reinforcing the clinical value of its liver-directed PHP platform (HEPZATO KIT/CHEMOSAT) for metastatic uveal melanoma and as a rationale to explore this approach in other liver-dominant cancers, while also reiterating extensive forward-looking risk factors around commercialization, reimbursement, supply chain, and regulatory oversight.